Xencor Inc (XNCR): Depreciation & Amortization
$10.51M
Year ended 2025-12-31
$10.17M
Trailing 12 months to 2026-06-30
+6.1%
3-year compound annual growth
+12.7%
5-year compound annual growth
+25.2%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.51M | -13.2% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $12.11M | +5.3% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $11.50M | +30.7% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $8.80M | +17.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $7.49M | +29.3% | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | $5.79M | +34.8% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $4.30M | +32.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $3.25M | +60.1% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $2.03M | +38.5% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $1.47M | +31.7% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $1.11M | +26.2% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $882.0K | +24.1% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $711.0K | +34.9% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $527.0K | n/a | 2015-02-23, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | $10.51M | -13.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.03M | +0.9% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $307.0K | -6.7% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $4.05M | -36.5% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $1.07M | -12.6% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $7.17M | -4.9% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
| Liquidia Corp (LQDA) | 2025-12-31 | $1.53M | -30.5% |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗